Search

Your search keyword '"Sale, Ben"' showing total 9 results
Start Over Author "Sale, Ben"
9 results on '"Sale, Ben"'

2. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Kater, Arnon P, Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H, van der Kevie-Kersemaekers, Anne-Marie F, Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J, Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E, Vizkelety, Tamas, and Forconi, Francesco

Published
2024
Full Text
View/download PDF

3. KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.

Author

Graham, Lara V., Fisher, Jack G., Doyle, Amber D. P., Sale, Ben, Del Rio, Luis, French, Albert J. E., Mayor, Neema P., Turner, Thomas R., Marsh, Steven G. E., Cragg, Mark S., Forconi, Francesco, Khakoo, Salim I., and Blunt, Matthew D.

Subjects
KILLER cells, IMMUNE response, LYMPHOCYTIC leukemia, CHRONIC leukemia, CANCER cells
Abstract

Strategies to mobilise natural killer (NK) cells against cancer include tumour-targeting antibodies, NK cell engagers (NKCEs) and the adoptive transfer of ex vivo expanded healthy donor-derived NK cells. Genetic and functional studies have revealed that expression of the activating killer immunoglobulin-like receptor KIR2DS2 is associated with enhanced function in NK cells from healthy donors and improved outcome in several different malignancies. The optimal strategy to leverage KIR2DS2+ NK cells therapeutically is however currently unclear. In this study, we therefore evaluated the response of KIR2DS2-expressing NK cells to activation against cancer with clinically relevant tumour-targeting antibodies and following ex vivo expansion. We identified that KIR2DS2high NK cells from patients with chronic lymphocytic leukaemia and hepatocellular carcinoma had enhanced activation in response to tumour-targeting antibodies compared to KIR2DS2- NK cells. However, the superior function of healthy donor derived KIR2DS2high NK cells was lost following ex vivo expansion which is required for adoptive transfer-based therapeutic strategies. These data provide evidence that targeting KIR2DS2 directly in cancer patients may allow for the utilisation of their enhanced effector function, however such activity may be lost following their ex vivo expansion. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Mutations in the IgG B cell receptor associated with class-switched B cell lymphomas

Author

Wasim, Laabiah, primary, Chu, Sin Wah Tooki, additional, Sale, Ben, additional, Pickard, Lucy, additional, Leonard, Simon, additional, Zhang, Lingling, additional, Tolarova, Helena, additional, Tean, Zhang Sung, additional, Engels, Niklas, additional, Calado, Dinis P., additional, Tarte, Karin, additional, Okosun, Jessica, additional, Forconi, Francesco, additional, and Tolar, Pavel, additional

Published
2024
Full Text
View/download PDF

5. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial

Author

Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, Forconi, Francesco, Genetica Sectie Genoomdiagnostiek, Kater, Arnon P., Arslan, Önder, Demirkan, Fatih, Herishanu, Yair, Ferhanoglu, Burhan, Diaz, Marcos Gonzalez, Leber, Brian, Montillo, Marco, Panayiotidis, Panayiotis, Rossi, Davide, Skarbnik, Alan, Tempescul, Adrian, Turgut, Mehmet, Mellink, Clemens H., van der Kevie-Kersemaekers, Anne Marie F., Lanham, Stuart, Sale, Ben, Del Rio, Luis, Popovic, Relja, Chyla, Brenda J., Busman, Todd, Komlosi, Viktor, Wang, Xifeng, Sail, Kavita, Pena, German E., Vizkelety, Tamas, and Forconi, Francesco

Published
2024

7. EUZOPHERODES VAPIDELLA (MANN, 1857) (LEP.: PYRALIDAE) NEW TO BRITAIN.

Author

SALE, BEN and SMITH, GRAEME J.

Subjects
*PYRALIDAE, *MOTHS, *SPECIES, *COLOR of insects, *ADULTS
Abstract

Euzopherodes vapidella (Mann, 1857) (Lep.: Pyralidae) is reported formally as a new species for Britain from Hertfordshire. the adult male moth is illustrated in colour as well as its genitalia. [ABSTRACT FROM AUTHOR]

Published
2021

8. Parallel Lines Grammodes bifasciata (Petagan, 1787) (Lep.; Erebidae) new to Britain from Cambridgeshire.

Author

BROWNSELL, TREVOR and SALE, BEN

Subjects
*NOCTUIDAE, *CHALK
Abstract

The article focuses on the geographical distribution of moth "Grammodes bifasciata". It mentions that "bifasciata" and "geometrica" possibly occur sympatrically throughout much of the Afro-tropical region, but only "bifasciata" occurs in North Africa and only "geometrica" occurs eastwards into Asia. It also mentions that immigration of species creates confusion over how to separate the two taxa.

Published
2020

9. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients

Author

Chiodin, Giorgia, Drennan, Samantha, Martino, Enrica Antonia, Ondrisova, Laura, Henderson, Isla, del Rio, Luis, Tracy, Ian, D’Avola, Annalisa, Parker, Helen, Bonfiglio, Silvia, Scarfo’, Lydia, Sutton, Lesley-Ann, Strefford, Jonathan C., Forster, Jade, Brake, Oliver, Potter, Kathleen N., Sale, Ben, Lanham, Stuart, Mraz, Marek, Ghia, Paolo, Stevenson, Freda K., and Forconi, Francesco

Abstract

Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM) levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within these low levels, CLL with relatively high sIgM (CLLhigh) progress more rapidly than CLL with low sIgM (CLLlow). During ibrutinib therapy, surviving CLL cells redistribute into the peripheral blood and can recover sIgM expression. Return of CLL cells to tissue may eventually recur, where cells with high sIgM could promote tumor growth. We analyzed time to new treatment (TTNT) following ibrutinib in 70 CLL patients (median follow-up of 66 months) and correlated it with pre-treatment sIgM levels and signaling characteristics. Pre-treatment sIgM levels correlated with signaling capacity, as measured by intracellular Ca2+mobilization (iCa2+), in vitro(r=0.70; p<0.0001). High sIgM levels/signaling strongly correlated with short TTNT (p<0.05), and 36% CLLhighversus 8% CLLlowprogressed to require a new treatment. In vitro,capacity of ibrutinib to inhibit sIgM-mediated signaling inversely correlated with pre-therapy sIgM levels (r=-0.68, p=0.01) or iCa2+(r=-0.71, p=0.009). In patients, sIgM-mediated iCa2+and ERK phosphorylation levels were reduced by ibrutinib therapy, but not abolished. The residual signaling capacity downstream of BTK was associated with high expression of sIgM, while it was minimal when sIgM expression was low (p<0.05). These results suggested that high sIgM levels facilitated CLL cell resistance to ibrutinib in patients. The CLL cells, surviving in the periphery with high sIgM expression, include a dangerous fraction, able to migrate to tissue and receive proliferative stimuli, which may require targeting by combined approaches.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results